-
Sinovac Amends Shareholder Rights Plan
prnasia
March 07, 2018
Sinovac Biotech Ltd. today announced that its board of directors has amended its shareholder rights plan. The amendment extends the expiration date of the plan from March 27, 2018 to March 27, 2019.
-
With a Collaboration Deal in Place with Merck, Cue Biopharma Plans $60 Million IPO
biospace
December 20, 2017
Cue BioPharma is on a roll, having recently signed a deal with Merck and is planning an initial public offering (IPO) to raise up to $60 million.
-
8 Possible Biopharma Takeover Targets for 2018
biospace
December 19, 2017
Many investors and analysts expect 2018 to be a big deal for mergers and acquisitions. The proposed tax plan not only reduced corporate income tax to about 21%, but also proposed a one-time amnesty of 10% for overseas funds to be repatriated.
-
RedHill Biopharma announces successful Phase III
pharmaasia
July 04, 2017
RedHill Biopharma announces successful Phase III top-line results with BEKINDA for Acute Gastroenteritis.
-
Personalised medicine, batch size of ONE, the new challenge to fill-finish?
contractpharma
June 30, 2017
Wenzel Novak PhD gives some considerations on container, environment, process and automation for small batch sizes in the downstream process of fill-finish…
-
Active Dashboard 2 Allows Easy Access to Process Performance Data
b3cnewswire
June 27, 2017
Advanced software solution ensures superior manufacturing quality and enables effective decision-making
-
Zytoprotec's Novel Dialysis Product Meets Both Endpoints in Phase II Study
b3cnewswire
June 13, 2017
Zytoprotec announced today the highly promising outcome of the Phase II study of its peritoneal dialysis fluid PD-protec®.
-
Sartorius Stedim Biotech Partners with Nova Biomedical
b3cnewswire
May 18, 2017
Firms combine ambr® technology with the BioProfile® FLEX2;Unique tool will allow massive quantities of cell culture data to be collected during upstream processing QbD studies.
-
Espero Pharma and Armetheon Merge
contractpharma
April 25, 2017
Creates a premier cardiovascular focused biopharmaceutical company
-
Novartis obtains rights to use Parvus’ Navacim to develop products for T1D
pharmaceutical-technology
April 24, 2017
Biopharmaceutical company Parvus Therapeutics has entered a licence and collaboration agreement with Novartis for its lead, Navacim, to treat type 1 diabetes (T1D).